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Vascular remodeling is a pathological condition with structural changes of blood vessels. Both inside-out and outside-in hy-
pothesis have been put forward to describe mechanisms of vascular remodeling. An integrated model of these two hypotheses 
emphasizes the importance of immune cells such as monocytes/macrophages, T cells, and dendritic cells. These immune cells 
are at the center stage to orchestrate cellular proliferation, migration, and interactions of themselves and other vascular cells 
including endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and fibroblasts. These changes on vascular wall lead 
to inflammation and oxidative stress that are largely responsible for vascular remodeling. Mineralocorticoid receptor (MR) is a 
classic nuclear receptor. MR agonist promotes inflammation and oxidative stress and therefore exacerbates vascular remodel-
ing. Conversely, MR antagonists have the opposite effects. MR has direct roles on vascular cells through non-genomic or ge-
nomic actions to modulate inflammation and oxidative stress. Recent studies using genetic mouse models have revealed that 
MR in myeloid cells, VSMCs and ECs all contribute to vascular remodeling. In conclusion, data in the past years have demon-
strated that MR is a critical control point in modulating vascular remodeling. Studies will continue to provide evidence with 
more detailed mechanisms to support this notion.  
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What is vascular remodeling? A simple and straightforward 
and possibly the most correct answer is that any structural 
changes of blood vessels are called vascular remodeling [1]. 
The causes of these changes range from pressure, flow and 
atherosclerotic stimuli, to mechanical injury such as balloon 
angioplasty and stent implantation during endovascular in-
terventions. The changes can be on the vascular wall, the 
luminal diameter, or both. Although the changes on the 
vascular wall and luminal diameter often happen together, 
there are situations that only one of them alters. For exam-
ple, Glagov and colleagues [2] found that the luminal diam-
eter of atherosclerotic human coronaries remained constant 
until the percent stenosis exceeded 40%, whereas the vas-
cular wall had dramatically changed because of atheroscle-
rosis. These structural changes are often accompanied by 
functional alterations of the blood vessels. Therefore, vas-
cular remodeling is closely associated with the pathophysi-
ology of a series of cardiovascular diseases such as athero-
sclerosis and restenosis, cerebrovascular diseases such as 
stroke, as well as hypertension. In this review, I will discuss 
the roles of mineralocorticoid receptor, a member of the 
nuclear receptor superfamily that controls numerous critical 
aspects of cellular functions under physiological or patho-
physiological conditions, in vascular remodeling. This arti-
cle will not cover vascular remodeling in embryonic devel-
opment or tumor growth, even though structural changes of 
blood vessels also happen in both processes [3,4]. 
810 Duan SZ   Sci China Life Sci   August (2014) Vol.57 No.8 
1  The mechanisms of vascular remodeling: the 
inside-out and outside-in hypotheses  
At least two different models have been put forward to de-
scribe the process of vascular remodeling, the inside-out 
hypothesis and outside-in hypothesis [5,6]. Traditionally, 
the vascular remodeling is considered as an inside-out pro-
cess. In this model, loss of endothelial integrity is a starting 
point followed by expression of surface adhesion molecules 
and inflammatory mediators that propel adhesion and 
transmigration of circulating monocytes into vascular wall. 
The causes of endothelial injury include mechanical injury, 
chemical stimuli, insulin resistance and associated glucose 
intolerance, dyslipidemia, hypertension, increased oxidation, 
thrombosis, and vascular inflammation [7]. Monocytes fur-
ther differentiate into macrophages in the vascular wall and 
traditionally this process had been considered as a continu-
ous one for the presence of monocytes/macrophages to 
function without excessive proliferation in the progression 
of vascular remodeling [8]. However, recent studies have 
demonstrated that in the process of atherosclerosis macro-
phages in the plaque maintain its population largely by pro-
liferation after the initial migration of monocytes [9]. Either 
way, macrophages in the vascular wall interact with vascu-
lar smooth muscle cells (VSMCs) in the media directly or 
through secreted inflammatory chemokines, cytokines and 
reactive oxygen species (ROS). Consequently, VSMCs pro-
liferate and migrate to subendothelial space and participate 
in repairing of damaged endothelium, formation of plaque 
or neointima, and vascular remodeling. In addition, VSMCs 
may dedifferentiate into myofibroblasts, contributing to 
vascular remodeling [5]. Other immune cells such as neu-
trophils, dendritic cells (DCs), T cells, B cells, and mast 
cells also play important roles in development and progres-
sion of atherosclerosis [10]. Fibroblasts are in general con-
sidered as bystanders in this model. 
In contrast, the outside-in hypothesis proposes that injury 
and immune response are initiated in the adventitia and 
progressed inward to the media and intima [5,6]. In this 
model, fibroblasts in the adventitia are highly active. In re-
sponse to vascular stress or injury, adventitia fibroblasts are 
often among the first cells to be activated in the vascular 
wall, accompanied by activation of immune cells such as T 
cells, DCs, and macrophages. Besides their traditional func-
tion of secreting extracellular matrix (ECM), activated and 
highly proliferated fibroblasts play central roles in vascular 
remodeling through the following aspects. First, these acti-
vated fibroblasts are considered as capable of executing 
immune functions. They express receptors such as toll-like 
receptors (TLRs) and NOD-like receptors (NLRs) to medi-
ate immune response. Further, they produce chemokines 
and cytokines such as monocyte chemotactic protein-1 
(MCP1), regulated upon activation, normal T cell expressed  
and secreted (RANTES), interleukin 6 (IL6), and stromal 
cell-derived factor 1 (SDF-1). Secondly, fibroblasts interact 
with activated immune cells (T cells, DCs, and macrophag-
es), ECs and VSMCs, either directly through cell-cell inter-
actions or through chemokines, cytokines and ROS. Mac-
rophages in this model are mostly regarded as resident ones 
or being differentiated from monocytes recruited from the 
vasa vasorum of the adventitia locally. In addition, prolifer-
ated fibroblasts can migrate to the media and intima, or  
differentiate into myofibroblasts that subsequently migrate 
to the media and intima, contributing to vascular remodel-
ing [11].  
2  An integrated model of mechanisms: immune 
cells at the center stage of vascular remodeling  
The two seemly contrasting hypotheses can come together 
and therefore I propose an integrated model for the mecha-
nisms of vascular remodeling (Figure 1). For instance, in 
the procedure of stent, dramatic endothelial damages are 
accompanied by stretch stimulus of the whole blood vessels 
including the adventitia. It is possible that both mechanisms 
execute and propel each other. The inside-out process leads 
to macrophage accumulation in the subendothelial space 
and interacting with endothelial cells (ECs) and VSMCs. 
The macrophages may also accumulate in the adventitia and 
interact with fibroblasts and other immune cells, which in 
turn induce an outside-in process. The adventitia may also 
sense the stretch at the same time of endothelial injury and 
ignite an outside-in process by activating local macrophages, 
fibroblasts, T cells, and DCs. Of course, it is possible that 
the inside-out process is more dominant in pathological 
conditions such as atherosclerosis and the outside-in process 
is more dominant in others such as hypertension.  
In either inside-out, outside-in, or integrated hypothesis, 
the immune cells play central roles in vascular remodeling. 
They respond to stress and injury, migrate into or proliferate 
in the vascular wall, and interact with other vascular cells. 
Monocytes/macrophages are a subset of these immune cells 
that have drawn much attention. Interestingly, macrophages 
predominantly accumulate in the adventitia in various mod-
els of vascular remodeling such as angiotensin II (Ang II)- 
induced, pressure overload-induced, and wire injury-   
induced [12–14], although macrophages-derived foam cells 
largely accumulate in the subendothelial area to form plaque 
in atherosclerosis. This implies that even if the macrophages 
come from the systemic circulation according to the in-
side-out hypothesis, these cells can ultimately dwell in the 
adventitia and interact with cells including fibroblasts and 
other immune cells there. These immune cells (mono-
cytes/macrophages, T cells, DCs) interact with each other 
and with ECs, VSMCs, and fibroblasts, driving the whole 
process of vascular remodeling (Figure 1).
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Figure 1 (color online)  An integrated model for mechanisms of vascular remodeling. This proposed model is an integration of the inside-out hypothesis 
and outside-in hypothesis. Endothelial injuries initiate an inside-out process that leads to macrophage accumulation in the subendothelial space and interact-
ing with endothelial cells and vascular smooth muscle cells through cell-cell interactions or secreted chemokines, cytokines and reactive oxygen species 
(ROS). Macrophages also migrate to and accumulate in the adventitia and interact with fibroblasts and other immune cells, which in turn induce an out-
side-in process. Simultaneously, the adventitia senses the stress and ignites an outside-in process by activating local macrophages, fibroblasts, T cells, and 
dendritic cells, all of which ultimately propel the inside-out process. In such way, the inside-out process and outside-in process act in concert and reinforce 
each other, being orchestrated by immune cells at the center stage and driving the whole course of vascular remodeling. 
3  Mineralocorticoid receptor and vascular re-
modeling 
Mineralocorticoid receptor (MR) is a classic steroid recep-
tor in the nuclear receptor superfamily [15]. To exert its 
genomic actions, MR binds to mineralocorticoids (primarily 
aldosterone), translocates into nucleus, binds as homodi-
mers to response elements of target genes, and therefore 
regulates their expression. The target genes of MR include 
those important in water-electrolyte homeostasis and blood 
pressure regulation, inflammation, oxidative stress, and  
fibrosis [16]. Recent studies have revealed that MR also  
has non-genomic actions by interactions with signaling 
pathways such as epidermal growth factor (EGF)/EGFR 
pathway and Ang II/type 1 Ang II receptors (AT1R) path-
way [16]. 
It is now well accepted that the function of MR is far 
beyond its traditional roles in epithelial cells to control wa-
ter-electrolyte homeostasis and blood pressure. Clinical 
studies have continuously and convincingly demonstrated 
the effectiveness of MR antagonists (spironolactone and 
eplerenone) in treating heart failure patients [1719]. 
Mounting evidence from basic research has illustrated the 
critical functions of this nuclear receptor in cardiovascular 
system. 
MR is expressed in vascular cells and the vasculature is 
generally regarded as an aldosterone-responsive tissue [20]. 
The concentration of glucocorticoids in the bloodstream is 
over 100 times higher than that of aldosterone and MR 
binds to both with similar affinity. Therefore, MR has the 
potential to bind to aldosterone only in tissues that express 
11β-hydroxysteroid dehydrogenase type 2 (11βHSD2), an 
enzyme that inactivates glucocorticoids. Traditionally, kid-
ney and colon are considered as aldosterone sensitive tis-
sues because of the high level of expression of 11βHSD2. 
More recent studies, however, have revealed that vascular 
cells including VSMCs and ECs express 11βHSD2 as well, 
indicating that blood vessels are aldosterone-responsive. It 
remains to be determined whether this enzyme is expressed 
in macrophages or other immune cells. 
3.1  Aldosterone and vascular remodeling 
Both epidemiological studies and animal studies have 
shown the importance of aldosterone in vascular remodeling. 
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Circulating level of aldosterone is an independent predictor 
of cardiovascular ischemia according to epidemiological 
studies [2123]. When blood pressure is comparable, pa-
tients with hyperaldosteronism have drastically increased 
risk of stroke and myocardial infarction. These results sug-
gest that aldosterone may promote atherosclerosis and 
plaque rupture in humans independent of its impact on 
blood pressure and that aldosterone and MR play important 
roles in vascular biology. Animal studies have also shown 
that aldosterone increases atherosclerosis in apoE knockout 
mice and this effect can be attenuated by blood pressure 
reduction [24]. More recently, aldosterone was found to 
promote early atherosclerosis and plaque inflammation in 
apoE knockout mice at a lower dose that did not elevate 
blood pressure, indicating that aldosterone may also directly 
affect atherosclerosis in animal models independent of its 
impact on blood pressure [25]. In addition, aldosterone in-
fusion induces vascular fibrosis and remodeling in rats    
in the setting of high salt [26]. In a swine model of     
balloon angioplasty aldosterone tends to exacerbate colla-
gen accumulation and constrictive remodeling of coronary 
arteries [27]. 
Aldosterone increases inflammation and oxidative stress 
in different vascular cells [26,28,29]. MR activation stimu-
lates infiltration of inflammatory cells including monocytes, 
macrophages and lymphocytes and promotes expression of 
inflammatory markers in the vasculature. Meanwhile, MR 
activation upregulates oxidative stress by increasing expres-
sion and activity of NADPH oxidases (NOX), production of 
ROS, and mitochondrial electron transport uncoupling. 
Given the vicious cycle of inflammation and oxidative 
stress, excessive aldosterone stimulates the two components 
that propel each other, promoting proliferation and migra-
tion of vascular cells, ECM deposition, and ultimately vas-
cular remodeling. 
3.2  MR antagonists and vascular remodeling 
Both eplerenone and spironolactone attenuate collagen ac-
cumulation and constrictive remodeling of coronary arteries 
without affecting the size of neointima in a swine model of 
balloon angioplasty [27]. In a swine model of stenting, ep-
lerenone suppresses neointima formation, vascular fibrosis 
and remodeling [30]. Spironolactone inhibits Ang II-   
induced increase in media-to-lumen ratio of mesenteric re-
sistance arteries and decrease in acetylcholine-induced vas-
odilation while decreasing blood pressure and oxidative 
stress in a rat model [31]. Similarly, structural and function-
al abnormalities induced by high salt in spontaneously hy-
pertensive rats were inhibited by eplerenone [32]. Subse-
quent data using Ang II overproducing transgenic mice 
showed that spironolactone improved vascular remodeling 
independent of blood pressure [33]. More recently, spirono-
lactone has been shown to attenuate pulmonary vascular 
resistance and pulmonary vascular remodeling in an exper-
imental pulmonary hypertension mouse model [34]. In ad-
dition, MR antagonists can inhibit atherosclerosis in differ-
ent animal models [3537]. Mechanistically, blockade of 
MR by antagonists inhibits oxidative stress and/or inflam-
mation and therefore breaks the vicious cycle. These data 
further demonstrated the importance of MR in vascular re-
modeling, providing foundations for further investigations 
on cell type-specific functions of MR. 
3.3  Myeloid MR and vascular remodeling 
Myeloid cells play important roles in atherosclerosis and 
restenosis. Functions of myeloid MR in vascular remodeling 
have been studied using a knockout mouse model. When 
challenged with a combination of a NOS inhibitor, NG-nitro- 
L-arginine methyl ester (L-NAME), and Ang-II, myeloid 
MR knockout (MMRKO) mice had decreased vascular fi-
brosis and remodeling, in addition to suppressed cardiac 
remodeling [12]. Macrophage infiltration in heart and aorta 
was almost completely blocked by myeloid MR deletion. 
Intriguingly, blood pressure was higher in the MMRKO 
mice, suggesting that the cardiovascular protection of mye-
loid MR deficiency was not because of its impact on blood 
pressure. Further, MR activation by aldosterone stimulated 
pro-inflammatory M1 polarization of macrophages and that 
MRKO or MR antagonists resulted in anti-inflammatory 
M2 polarization of macrophages by regulating a host of M1 
and M2 genes. These M1 genes include interleukin 1 
(IL1), IL6, IL12, monocyte chemotactic protein-1 (MCP1), 
regulated upon activation, normal T cell expressed and se-
creted (RANTES), and tumor necrosis factor- (TNF). M2 
genes include arginase 1 (Arg1), chemokine (C-C motif) 
ligand 7 (CCL7), CCL17, found in inflammatory zone 1 
(FIZZ1), coagulation factor XIII a1 (F13a1), IL10, macro-
phage scavenger receptor (MSR), and T-lymphocyte-   
derived eosinophil chemotactic factor (YM1). Additionally, 
MRKO or MR antagonists decreased expression of pro- 
fibrotic genes including plasminogen activator inhibitor-1 
(PAI1), transforming growth factor  (TGF), as well as 
increased expression of anti-fibrotic genes including cyste-
ine-rich, angiogenic inducer 61 (CYR61), high-tempera- 
ture requirement A1 (HTRA1), and pyruvate dehydrogenase 
kinase 4 (PDK4). More recently, these phenotypes were 
also demonstrated in human monocytes/macrophages 
[38,39]. Therefore, MR acts as a strong control point for 
macrophage polarization that may ultimately explain the 
beneficial effects of MRKO on vascular remodeling (Figure 
2). The detailed mechanisms are still under intensive inves-
tigations. 
3.4  VSMC MR and vascular remodeling 
VSMC-specific knockout of MR (SMRKO) effectively 
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Figure 2 (color online)  Functions of macrophage mineralocorticoid receptor (MR) in vascular remodeling. Aldosterone promotes expression of 
pro-inflammatory genes and drives a classically activated (M1) phenotype of macrophages. Conversely, MR deficiency (MRKO) or antagonist suppresses 
pro-inflammatory gene expression while promotes anti-inflammatory gene expression and therefore drives an alternatively activated (M2) phenotype. 
MRKO or antagonist also decreases pro-fibrotic gene expression while increases anti-fibrotic gene expression. These effects ultimately translate into delete-
rious impacts of aldosterone and beneficial impacts of MRKO or antagonist on vascular remodeling. IL1: interleukin 1; MCP1: monocyte chemotactic 
protein-1; RANTES: regulated upon activation, normal T cell expressed and secreted; TNF: tumor necrosis factor-; Arg1: arginase 1; CCL7: chemokine 
(C-C motif) ligand 7; FIZZ1: found in inflammatory zone 1; F13a1: coagulation factor XIII a1; MSR: macrophage scavenger receptor; YM1: 
T-lymphocyte-derived eosinophil chemotactic factor; PAI1: plasminogen activator inhibitor-1; TGF: transforming growth factor ; CYR61: cysteine-rich, 
angiogenic inducer, 61; HTRA1: high-temperature requirement A1; PDK4: pyruvate dehydrogenase kinase 4. 
blocked age-associated hypertension through decreasing 
vascular myogenic tone and vasoconstriction response, 
without alterations in vascular structure or renal function 
[40]. However, in a wire-induced carotid injury model in 
combination with aldosterone infusion, SMRKO dramati-
cally decreased VSMC proliferation and vascular fibrosis 
that were induced by aldosterone or injury alone, through a 
placental growth factor/type 1 vascular endothelial growth 
factor receptor (VEGFR1) pathway [41].  
At the cellular level, MR plays direct roles in VSMCs 
through rapid non-genomic pathways or slower genomic 
effects (Figure 3). A large amount of data have been gener-
ated on studying the non-genomic actions of MR in VSMCs 
[20,26,42,43]. Aldosterone has been shown to rapidly 
transactivate EGFR or platelet-derived growth factor recep-
tor (PDGFR), which are followed by activation of non-  
receptor tyrosine kinase c-Src. Subsequently, c-Src phos-
phorylates and activates mitogen-activated protein kinases 
(MAPK) including ERK, JNK, and P38. Meanwhile, c-Src 
upregulates redox pathways through activation of NOX. 
Genomic actions of MR have also been reported in VSMCs. 
MR has been demonstrated to regulate expression of genes 
such as dual specificity protein phosphatase 1 (Dusp1), 
plasminogen activator inhibitor-1 (PAI-1), connective tissue 
growth factor (CTGF), collagen I, and collagen III [20]. 
Importantly, these phenotypes of aldosterone can be inhib-
ited by MR antagonists, indicating the dependency of MR. 
Furthermore, both non-genomic and genomic actions are 
potentiated by crosstalk between Ang II/AT1R pathway and 
aldosterone/MR pathway [20,42]. In the end, these 
non-genomic and genomic actions of MR in VSMCs lead to 
inflammation, oxidative stress, proliferation, migration, and 
ECM deposition, contributing to vascular remodeling. 
3.5  EC MR and vascular remodeling 
Either at baseline or stimulated with Ang II or endothelin 1, 
endothelial cell-specific MR overexpression (ECMROE) 
mice had significantly elevated blood pressure that could be 
reversed by MR antagonist. Furthermore, the resistance 
arteries from ECMROE mice had increased contractile re-
sponse to vasoconstrictors. Intriguingly, despite these func-
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Figure 3 (color online)  Functions of vascular smooth muscle cell mineralocorticoid receptor (MR) in vascular remodeling. On one hand, aldosterone binds 
to MR and regulates expression of genes such as dual specificity protein phosphatase 1 (Dusp1), plasminogen activator inhibitor-1 (PAI-1), connective tissue 
growth factor (CTGF), collagen I (Coll-I), and collagen III (Coll-III), leading to genomic effects in vascular smooth muscle cells (VSMCs). On the other 
hand, MR transactivates epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor (PDGFR) and subsequently activates a 
non-genomic cascade involving non-receptor tyrosine kinase c-Src and mitogen-activated protein kinases (MAPK) including ERK, JNK, and P38. c-Src also 
activates NADPH oxidases (NOX) directly. These non-genomic and genomic actions of MR in VSMCs lead to inflammation, oxidative stress, proliferation, 
migration, and extracellular matrix (ECM) deposition, contributing to vascular remodeling. MR deficiency (MRKO) in VSMCs or antagonist of MR largely 
blocks the effects of aldosterone.  
tional changes, no morphological alterations were observed 
between ECMROE mice and littermate control mice [44]. 
EC MR knockout (ECMRKO) prevented endothelial dys-
function, measured by endothelium-dependent vasodilation 
of aortic rings, in mouse models of both obesity and aldos-
terone infusion [45]. Further experiments showed that 
ECMRKO could prevent aldosterone-induced endothelial 
dysfunction in aortas but not in mesenteric arteries, sug-
gesting differential function of endothelial MR in large 
conduit arteries vs. resistance vessels [46]. Blood pressure 
was not different between ECMRKO mice at baseline or 
stimulated with DOCA. The functions of endothelial MR in 
vascular remodeling are worth further exploration in differ-
ent models and with more mechanistic depth. 
At the cellular level, MR also plays direct roles in ECs 
(Figure 4). In vascular ECs, aldosterone has been shown to 
promote expression of intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
and therefore adhesion of leukocytes [47,48]. Aldosterone 
induces ROS generation in ECs by activation of NOX 
through a c-Src/Rac1 pathway or by suppression of glu-
cose-6-phosphate dehydrogenase (G6PD) activity, in an 
MR-dependent manner [49,50]. Further, although there are 
conflicting data [51], MR activation has been shown to de-
crease endothelial nitric oxide synthase (eNOS) and produc-
tion of nitric oxide (NO) by activation of protein phospha-
tase 2A (PP2A) [20,52]. In addition, aldosterone has been 
shown to activate ERK through phosphoinositide 3-kinase 
(PI3K) in ECs [51]. A link between aldosterone and EGFR 
has also been proposed in ECs [43]. It is likely that in these 
cells aldosterone also transactivates EGFR that subsequent-
ly activates c-Src, a pathway that is operated in VSMCs. It 
remains to be determined whether PP2A and PI3K are acti-
vated by c-Src, which has been reported in other systems, or 
by other mechanisms. Consequently, MR activation in ECs 
promotes inflammation, oxidative stress, and endothelial 
dysfunction, contributing to vascular remodeling. 
4  Conclusion and future directions 
Vascular remodeling is a complicated pathological process 
involving multiple types of cells. Inflammation and oxida-
tive stress are the major driving forces of vascular remodel-
ing. Studies in the past years have demonstrated that MR is 
a critical control point to break the vicious cycle of inflam-
mation and oxidative stress in various vascular cells. These 
data support that MR is a potential target for modulating 
vascular remolding and warrant clinical studies to test ther-
apeutic effects of MR antagonists that have already been 
used for heart failure patients.  
MR will continue to be an interesting and important re-
search topic in vascular remodeling with many questions 
unanswered. For instance, functions of MR in T cells and 
DCs in vascular remodeling are still to be investigated. MR 
is abundantly expressed in DCs and may be also expressed 
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Figure 4 (color online)  Functions of endothelial mineralocorticoid receptor (MR) in vascular remodeling. Aldosterone binds to MR and regulates expres-
sion of genes such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and glucose-6-phosphate dehydrogenase 
(G6PD) in endothelial cells (ECs). The non-genomic effects of MR in ECs are less clear. MR may transactivate epidermal growth factor receptor (EGFR) 
and subsequently activate a non-genomic cascade involving non-receptor tyrosine kinase c-Src and/or phosphoinositide 3-kinase (PI3K)/ERK. c-Src acti-
vates NADPH oxidases (NOX) through Rac1 and may also activate protein phosphatase 2A (PP2A) and/or PI3K. PP2A can decrease endothelial nitric oxide 
synthase (eNOS) and production of nitric oxide. These effects of MR in ECs lead to inflammation, oxidative stress, and endothelial dysfunction, contributing 
to vascular remodeling. MR deficiency (MRKO) in ECs or antagonist of MR largely blocks the effects of aldosterone. The question marks (?) indicate possi-
ble links that remain to be further confirmed. 
in T cells at a much lower level [53,54]. It has been shown 
that aldosterone promotes activation of CD8+ T cells and 
Th17 polarization of CD4+ T cells and that these effects are 
dependent on activation of MR and modulation of DC func-
tion by aldosterone [54]. More recently, it has been reported 
that MR activation reduces the amount of circulating naïve 
CD4+ and CD8+ T cells in human subjects, further suggest-
ing important functions of MR in T cells [55]. However, 
direct roles of MR in T cells or DCs have not been reported 
in any setting of vascular remodeling. In addition, detailed 
molecular mechanisms of MR in immune cells and vascular 
cells need to be further delineated.  
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